Similarly, NF-κB activation also promotes proliferation and survival of normal and leukemic B-cells and plays a role in chemotherapies and targeted drug resistance [31, 37, 38], and is one mediator of STAT3 activation in CLL [31, 39]. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.